Solana Company announced strong Q3 2026 results with $3.4 million in revenue, primarily from staking, and a net income of $105.2 million, a significant turnaround from last year's loss. The company expanded its SOL holdings by purchasing approximately 125,000 SOL using proceeds from a $15 million registered direct offering priced above net asset value. Operationally, it achieved a 5.9% staking yield outperforming the Solana network average and launched its Pacific Backbone infrastructure. With growing institutional trust and a new Hong Kong headquarters, Solana Company is positioned to further bridge Asian financial institutions to the Solana ecosystem.
Solana Company’s Q3 2026 financial results provide context for readers interested in market dynamics. For readers following US stocks on Pluang, here is the market snapshot as of Nov 12, 2026 04:11 WIB: out of 150 priced US stocks, 92 rose and 58 fell. Notable movers include FCEL at USD 10.94 with a 1-day change of +6.42% and Pluang order activity of 90% Sell / 10% Buy, NVAX at USD 10.20 down 6.34% with 83% Sell / 17% Buy, and B at USD 39.77 down 5.91% with 0% Sell / 100% Buy.
Ashland Inc.'s board of directors declared a quarterly cash dividend of $0.42 per share, payable on December 15, 2026, to shareholders of record as of December 1, 2026. This dividend reflects the company's ongoing commitment to returning value to sha...
AeroVironment secured a $405 million international order for its LOCUST X3 high-energy laser weapon systems, enhancing counter-drone defense capabilities in the Middle East amid rising regional security threats. Following the announcement, AeroVironm...
Vestas Wind Systems reported Q3 2026 earnings per share of $0.13 and revenue of $6.34 billion, both below analyst expectations. The company's profit was impacted by weak sales volume and a broken turbine blade. Following the earnings miss, Vestas' sh...
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
